Rosen Law Firm Files Securities Class Action Lawsuit Against Aldeyra Therapeutics

Got story updates? Submit your updates here. ›

The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026. The lawsuit alleges that Aldeyra made false and/or misleading statements about the results of its reproxalap clinical trials, which were inconsistent and rendered any positive findings unreliable.

Why it matters

This lawsuit highlights the importance of transparency and accuracy in pharmaceutical companies' disclosures to investors, especially around clinical trial results that can significantly impact stock prices and investor confidence. The case raises questions about Aldeyra's handling of the reproxalap data and whether the company misled investors.

The details

The lawsuit alleges that Aldeyra defendants made false and/or misleading statements and/or failed to disclose that the results of the reproxalap clinical trials were inconsistent, rendering any purported positive findings unreliable. This allegedly caused investors to suffer damages when the true details about the trial results entered the market.

• The class period covers November 3, 2023 to March 16, 2026.
• Investors have until May 29, 2026 to move the court to serve as lead plaintiff.

What they’re saying

What’s next

The court will need to certify the class before the lawsuit can proceed. Investors have until May 29, 2026 to move the court to serve as lead plaintiff in the case.